Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06060041 · ClinicalTrials.gov registry record

IC-8 Apthera IOL New Enrollment Post Approval Study

A clinical trial of Cataract and Presbyopia, sponsored by Bausch & Lomb Incorporated.

Recruiting
Registry status
435
Enrollment target
14
Study locations

NCT06060041: Recruiting study of Cataract and Presbyopia, sponsored by Bausch & Lomb Incorporated.

NCT06060041 is a study of Cataract and Presbyopia that is actively recruiting participants, run by Bausch & Lomb Incorporated. The registered enrollment target is 435 participants, above the 223-participant average among 83 other Cataract trials with a reported enrollment target (95% higher). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06060041, a study of Cataract and Presbyopia, is actively recruiting participants, sponsored by Bausch & Lomb Incorporated.

RECRUITING
Registry status
435 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

Primary Outcome

Rates of additional Nd:YAG laser treatments in the eye implanted with the IC-8 Apthera intraocular lens (IOL) beyond the initial Nd:YAG laser treatment will be assessed through 24 months post IC-8 Apthera IOL implantation

Study Locations (14)

Florida

  • Argus Research Center - Cape Coral
  • Stephenson Eye Associates - Venice

New Jersey

  • Eye Associates of New Jersey - Dover
  • Northern New Jersey Eye Institute - South Orange

Alabama

  • Trinity Research Group, LLC - Dothan

California

  • Feinerman Vision Center - Newport Beach

Illinois

  • Virdi Eye Clinic and Laser Vision Center - Rock Island

Indiana

  • Price Vision Group - Indianapolis

Kansas

  • Grene Vision Group - Wichita

Michigan

  • Oakland Eye - Birmingham

Trial Details

FieldValue
Enrollment Target 435 participants
Start Date 2023-09-08
Est. Completion 2027-09-30
Bausch & Lomb Incorporated

174 total trials

What NCT06060041 shows while recruiting

NCT06060041 is an observational study that tracks outcomes without assigning an intervention. The registered 435 participants enrollment target is mid-sized for trials with a published cap, above the 223-participant average among 83 other Cataract trials with a reported enrollment target (95% higher).

The record links to 3 conditions, with Cataract appearing as the primary indexed condition, and to 0 interventions.

NCT06060041 lists 14 locations in 12 states (Florida, New Jersey, Alabama).

Frequently Asked Questions

What is clinical trial NCT06060041 about?

NCT06060041 is a clinical study titled "IC-8 Apthera IOL New Enrollment Post Approval Study". The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

What is the current status of trial NCT06060041?

This trial is currently recruiting. The enrollment target is 435 participants. The study started on 2023-09-08. Estimated completion is 2027-09-30.

What conditions does trial NCT06060041 study?

This clinical trial studies the following conditions: Cataract, Presbyopia, Posterior Capsule Opacification.

Who is sponsoring clinical trial NCT06060041?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06060041 being conducted?

This trial has 14 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06060041's enrollment target sits among peer trials

435 8th of 83 higher than 76 of 83 other Cataract trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05563220 · 435 participants · Phase 1

    Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

  • NCT07088926 · 435 participants · Phase 2

    A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  • NCT02622542 · 436 participants · NA

    ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy

  • NCT05918211 · 436 participants · Phase 3

    Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06060041, the US trial registry maintained by the National Library of Medicine. NCT06060041 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.